Buprenorphine and a CRF1 Antagonist Block the Acquisition of Opiate Withdrawal-Induced Conditioned Place Aversion in Rats
The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Conditioned place aversion in rats has face validity as a measure of the aversive stimulus effects of opiate withdrawal that reflects an important motivational component of opiate dependence. The purpose of the present study was to validate conditioned place aversion as sensitive to medications that will alleviate the aversive stimulus effects of opiate withdrawal in humans, and to extend this model to the exploration of the neuropharmacological basis of the motivational effects of opiate withdrawal. Male Sprague-Dawley rats were implanted with two subcutaneous morphine pellets and 5 days later began place conditioning training following subcutaneous administration of a low dose of naloxone. Animals were subjected to three pairings of a low dose of naloxone (15 microg/kg, s.c.) to one arm of a three-chambered place conditioning apparatus. Buprenorphine administered prior to each pairing dose-dependently blocked the place aversion produced by precipitated opiate withdrawal. A corticotropin-releasing factor-1 (CRF1) receptor antagonist (antalarmin) also reversed the place aversion produced by precipitated opiate withdrawal. Antalarmin did not produce a place preference or place aversion by itself in morphine-dependent rats. No effect was observed with pretreatment of the dopamine partial agonist terguride or the selective serotonin reuptake inhibitor fluoxetine. Also, chronic pretreatment with acamprosate (a glutamate receptor modulator used to prevent relapse in alcohol depend…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Administration of a CRF receptor antagonist has been found to decrease opioid withdrawal-induced negative emotional states (54) and attenuated heroin self-administration in animals with extended access to the drug (55).”
From Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice (2019) · cites this paper as [54]
Citations
Cites
Drug Addiction, Dysregulation of Reward, and Allostasis
Koob, G. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00195-0 · Cited by 2,953
Self-citationDrug abuse: hedonic homeostatic dysregulation
Koob, G. F., & Moal, M. L. (1997) · Science · doi:10.1126/science.278.5335.52 · Cited by 2,535 · cited 1×
“The purpose of the present study was to validate conditioned place aversion as sensitive to medications that will alleviate the aversive stimulus effects of opiate withdrawal in humans, and to extend this model to the exploration of the neuropharmacological basis of the motivational effects of…”
BackgroundSelf-citationKoob, G. F., Sanna, P. P., & Bloom, F. E. (1998) · Neuron · doi:10.1016/s0896-6273(00)80557-7 · Cited by 1,026
Self-citationJasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782 · cited 1×
“Buprenorphine’s partial agonist properties limit its abuse liability (Jasinski et al, 1978), and it recently has been approved for use in the treatment opiate dependence (Johnson and McCagh, 2000; Tzschentke, 2002; Substance Abuse and Mental Health Services Administration, 2002).”
BackgroundZobel, A. W., Nickel, T., Künzel, H. E., Ackl, N., Sonntag, A., Ising, M., & Holsboer, F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00016-9 · Cited by 705 · cited 1×
“…that blocked shockinduced freezing did not compromise HPA axis responses to stress (Deak et al, 1999), and in clinical study the CRF1 antagonist R121919 produced anxiolytic-like effects in depressed patients in the absence of effects on basal or CRF-stimulated HPA axis measures (Zobel et al, 2000).”
BackgroundDynamics of Drug Dependence: Implications of a Conditioning Theory for Research and Treatment
Wikler, A. (1973) · Archives of General Psychiatry · doi:10.1001/archpsyc.1973.01750350005001 · Cited by 648 · cited 2×
“Opiate addiction long has been thought to involve multiple sources of reinforcement (Wikler, 1973).”
BackgroundCorticotropin-releasing factor, norepinephrine, and stress
Koob, G. F. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00164-x · Cited by 629 · cited 2×
“Because norepinephrine may release CRF in the basal forebrain, and CRF activates norepinephrine function in the pons, there is the possibility of a feedforward system involved in the aversive stimulus effects of opiate withdrawal as well as stress in general (Koob, 1999; Valentino et al, 1993).”
BackgroundSelf-citationPich, E., Lorang, M., Yeganeh, M., Rodriguez de Fonseca, F., Raber, J., Koob, G., & Weiss, F. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-08-05439.1995 · Cited by 565 · cited 2×
“Studies using in vivo microdialysis have shown that rats withdrawn from chronic alcohol, withdrawn from chronic cocaine, and precipitously withdrawn from chronic cannabinoids show increases in the release of CRF from the central nucleus of the amygdala (Cummings et al, 1983; Merlo-Pich et al, 1995; Rodriguez de Fonsec…”
BackgroundSelf-citationA role for corticotropin releasing factor and urocortin in behavioral responses to stressors
Koob, G. F., & Heinrichs, S. C. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01991-5 · Cited by 531 · cited 1×
“These same central CRF systems are well documented to contribute to behavioral responses to stressors (Koob et al, 1994; Koob and Heinrichs, 1999).”
BackgroundSelf-citationAGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT
COWAN, A., LEWIS, J. W., & MACFARLANE, I. R. (1977) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1977.tb07532.x · Cited by 528 · cited 1×
“Buprenorphine is an opioid partial agonist at the m opioid receptor and a k opioid antagonist (Cowan et al, 1977).”
Background
Research works printed but not linked: 1
- Valentino RJ, Foote SL, Page ME (1993). The locus coeruleus as a site for integrating corticotropin-eleasing factor and noradrenergic mediation of stress responses. In: Tache Y, Rivier C (eds). Corticotropin-Releasing Factor and Cytokines: Role in the Stress Response (series title: Annals of the New York Academy of Sciences, Vol. 697). New York Academy of Sciences: New York. pp 173–188.
Cited by
Koob, G. F., & Volkow, N. D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.110 · Cited by 5,340
“Systemic administration of a CRF1 receptor antagonist and direct intracerebral administration of a peptide CRF1/CRF2 antagonist also decreased opioid withdrawal-induced place aversions (Stinus et al, 2005; Heinrichs et al, 1995).”
BackgroundSelf-citationTzschentke, T. M. (2007) · Addiction Biology · doi:10.1111/j.1369-1600.2007.00070.x · Cited by 1,336
A Role for Brain Stress Systems in Addiction
Koob, G. F. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.012 · Cited by 1,056
“A CRF1/CRF2 peptide antagonist injected into the central nucleus of the amygdala and systemic administration of CRF1 antagonists blocked conditioned place aversion associated with precipitated opiate withdrawal (Heinrichs et al., 1995; Stinus et al., 2005).”
Self-citationAddiction as a stress surfeit disorder
Koob, G. F., Buck, C. L., Cohen, A., Edwards, S., Park, P. E., Schlosburg, J. E., Schmeichel, B., Vendruscolo, L. F., Wade, C. L., Whitfield, T. W., et al. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.05.024 · Cited by 483
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript by naloxone in morphine-dependent rats (Stinus et al., 2005), and a CRF peptide antagonist injected into the CeA also reversed the place aversion produced by methylnaloxonium injected into the CeA (Heinrichs et al.,…”
BackgroundMethodSelf-citationRole of Corticotropin-Releasing Factor in Drug Addiction: Potential for Pharmacological Intervention
Logrip, M. L., Koob, G. F., & Zorrilla, E. P. (2011) · CNS Drugs · doi:10.2165/11587790-000000000-00000 · Cited by 476
Self-citationNeurobiological substrates for the dark side of compulsivity in addiction
Koob, G. F. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.043 · Cited by 458
“Systemic administration of a CRF1 receptor antagonist and direct intracerebral administration of a peptide CRF1/CRF2 antagonist also decreased opioid withdrawal-induced place aversions (Stinus et al., 2005; Heinrichs et al., 1995).”
Self-citationThe dark side of emotion: the addiction perspective
Koob, G. F. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.11.044 · Cited by 433
“Systemic administration of a CRF1 receptor antagonist and direct intracerebral administration of a peptide CRF1/CRF2 antagonist also decreased opioid withdrawal-induced place aversions (Stinus et al., 2005; Heinrichs et al., 1995; Contarino and Papaleo, 2005).”
BackgroundMethodInfluentialSelf-citationAddiction is a Reward Deficit and Stress Surfeit Disorder
Koob, G. F. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00072 · Cited by 397
Self-citationBrain stress systems in the amygdala and addiction
Koob, G. F. (2009) · Brain Research · doi:10.1016/j.brainres.2009.03.038 · Cited by 388
“Systemic administration of a CRF1 receptor antagonist and direct intracerebral administration of a peptide CRF1/CRF2 antagonist also decreased opioid withdrawal-induced place aversions (Stinus et al., 2005;Heinrichs et al., 1995).”
BackgroundMethodSelf-citationDrug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development
Koob, G. F. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000083 · Cited by 337
“Systemic CRF receptor antagonist and functional noradrenergic receptor antagonist administration blocked naloxone-precipitated conditioned place aversion in opioid-dependent rats (Schulteis et al., 1998; Stinus et al., 2005).”
BackgroundSelf-citationKutlu, M. G., & Gould, T. J. (2016) · Learning & Memory · doi:10.1101/lm.042192.116 · Cited by 317
The role of CRF and CRF-related peptides in the dark side of addiction
Koob, G. F. (2010) · Brain Research · doi:10.1016/j.brainres.2009.11.008 · Cited by 290
“Using the place aversion model, a CRF1 antagonist also blocked the development of conditioned place aversion induced by precipitated opioid withdrawal in opioid-dependent rats (Stinus et al., 2005).”
Self-citationDrug addiction: Pathways to the disease and pathophysiological perspectives
Le Moal, M., & Koob, G. F. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.10.006 · Cited by 283
“…CRF antagonists block the increased anxiety or aversive responses associated with precipitated drug withdrawal (for review: Koob and Le Moal, 2005a) and more specifically, a competitive CRF1 antagonist block the development of place aversion to precipitated opiate withdrawal (Stinus et al., 2005).”
BackgroundSelf-citationFunk, C. K., Zorrilla, E. P., Lee, M.-J., Rice, K. C., & Koob, G. F. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.063 · Cited by 276
“…to inhibit fear conditioning (Deak et al 1999), inhibit CRF- and novelty-induced anxiety-like behaviors (Zorrilla et al 2002), inhibit the locomotor activating effects of CRF (Zorrilla et al 2002), and inhibit naloxone-precipitated place aversion in morphine-dependent animals (Stinus et al 2005).”
BackgroundSelf-citationThe dark side of food addiction
Parylak, S. L., Koob, G. F., & Zorrilla, E. P. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.04.063 · Cited by 257
“Analogously, CRF1 antagonists ameliorated aversive- or anxiety-like states during withdrawal from alcohol [59, 71, 72], opiates [73, 74], benzodiazepines [75], cocaine [76, 77], and nicotine [66].”
BackgroundSelf-citationCorticotropin releasing factor: A key role in the neurobiology of addiction
Zorrilla, E. P., Logrip, M. L., & Koob, G. F. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.01.001 · Cited by 254
“Furthermore, the aversive state of opiate withdrawal and the decreased brain reward function associated with nicotine withdrawal are both CRF1 receptor-dependent (Contarino and Papaleo, 2005; Stinus et al., 2005; Bruijnzeel et al., 2007, 2009, 2012; Garcia-Carmona et al., 2012).”
BackgroundSelf-citationWalker, D. L., & Davis, M. (2008) · Brain Structure and Function · doi:10.1007/s00429-008-0183-3 · Cited by 231
“On the other hand, there is considerable evidence to show that CRF (Heinrichs et al. 1995; Contarino and Papaleo 2005; Stinus et al. 2005) and the BNST, and more specifically norepinephrine acting on b-adrenergic receptors in the BNST, are involved in the affective state associated with drug withdrawal.”
BackgroundSmith, R. J., & Aston-Jones, G. (2008) · Brain Structure and Function · doi:10.1007/s00429-008-0191-3 · Cited by 206
Opposing mechanisms mediate morphine- and cocaine-induced generation of silent synapses
Graziane, N. M., Sun, S., Wright, W. J., Jang, D., Liu, Z., Huang, Y. H., Nestler, E. J., Wang, Y. T., Schlüter, O. M., & Dong, Y. (2016) · Nature Neuroscience · doi:10.1038/nn.4313 · Cited by 176
“These doses and routes of drug delivery were selected as they produce equivalent degrees of locomotor sensitization and conditioned reward for the two drugs 16, 51 .”
The therapeutic potential of CRF1 antagonists for anxiety
Zorrilla, E. P., & Koob, G. F. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.7.799 · Cited by 176
Self-citationProgress in corticotropin-releasing factor-1 antagonist development
Zorrilla, E. P., & Koob, G. F. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.02.011 · Cited by 167
Self-citationMedications development: Successes and challenges
Vocci, F., & Ling, W. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.010 · Cited by 160
Edwards, S., Vendruscolo, L. F., Schlosburg, J. E., Misra, K. K., Wee, S., Park, P. E., Schulteis, G., & Koob, G. F. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.11.006 · Cited by 158
“related behaviors associated with both heroin (Heinrichs et al., 1995; Stinus et al., 2005) and alcohol (Valdez et al.”
BackgroundSelf-citationNeurobiology of dysregulated motivational systems in drug addiction
Edwards, S., & Koob, G. F. (2010) · Future Neurology · doi:10.2217/fnl.10.14 · Cited by 157
“Both s ystemic administration of a CRF 1 -receptor antagonist and direct intracerebral administration of a peptide CRF-receptor antagonist decreased drug withdrawal-induced anxiety-like or a versive responses [43–50].”
BackgroundSelf-citationDevelopment of pharmacotherapies for drug addiction: a Rosetta stone approach
Koob, G. F., Kenneth Lloyd, G., & Mason, B. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2828 · Cited by 154
Self-citationCraving in Opioid Use Disorder: From Neurobiology to Clinical Practice
Kakko, J., Alho, H., Baldacchino, A., Molina, R., Nava, F. A., & Shaya, G. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00592 · Cited by 140
“Administration of a CRF receptor antagonist has been found to decrease opioid withdrawalinduced negative emotional states (54) and attenuated heroin selfadministration in animals with extended access to the drug (55).”
BackgroundNeurobiological mechanisms of addiction: focus on corticotropin-releasing factor.
Koob, G. F., & Zorrilla, E. P. (2010) · PubMed · Cited by 167
Self-citationZanos, P., Georgiou, P., Wright, S. R., Hourani, S. M., Kitchen, I., Winsky-Sommerer, R., & Bailey, A. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.285 · Cited by 133
Hedonic homeostatic dysregulation as a driver of drug-seeking behavior
Koob, G. F. (2008) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2009.04.002 · Cited by 114
Self-citationThe intersection of stress and reward: BNST modulation of aversive and appetitive states
Ch'ng, S., Fu, J., Brown, R. M., McDougall, S. J., & Lawrence, A. J. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.01.005 · Cited by 112
Zorrilla, E. P., Heilig, M., de Wit, H., & Shaham, Y. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.12.017 · Cited by 108
Self-citationContarino, A., & Papaleo, F. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506999102 · Cited by 107
Bruijnzeel, A. W., Zislis, G., Wilson, C., & Gold, M. S. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301192 · Cited by 110
“For example, antagonism of CRF receptors has been shown to prevent the development of opioid withdrawal-induced conditioned place aversion (Heinrichs et al, 1995; Stinus et al, 2005).”
BackgroundKehne, J. H., & Cain, C. K. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.08.011 · Cited by 105
“The authors have argued that the BNST mediates more prolonged, sustained states of anxiety.”
BackgroundInfluentialDynamic vaccine blocks relapse to compulsive intake of heroin
Schlosburg, J. E., Vendruscolo, L. F., Bremer, P. T., Lockner, J. W., Wade, C. L., Nunes, A. A. K., Stowe, G. N., Edwards, S., Janda, K. D., & Koob, G. F. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219159110 · Cited by 105
“Conditioned place preference paradigm consisted of a two-chambered apparatus, differentiated by wall (dots or stripes) and textured plastic flooring (prismatic or cracked ice), with a small central alley (44).”
MethodSelf-citationGreenwell, T. N., Funk, C. K., Cottone, P., Richardson, H. N., Chen, S. A., Rice, K. C., Zorrilla, E. P., & Koob, G. F. (2009) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00142.x · Cited by 87
“Several reports provide support for the latter possibility (Heinrichs et al. 1995; Lu et al. 2000; Funada, Hara & Wada 2001; Contarino & Papaleo 2005; Stinus et al. 2005).”
BackgroundResultInfluentialSelf-citationEndogenous opiates and behavior: 2005
Bodnar, R. J., & Klein, G. E. (2006) · Peptides · doi:10.1016/j.peptides.2006.07.011 · Cited by 96
Cortico-Amygdala Coupling as a Marker of Early Relapse Risk in Cocaine-Addicted Individuals
McHugh, M. J., Demers, C. H., Salmeron, B. J., Devous, M. D., Stein, E. A., & Adinoff, B. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00016 · Cited by 76
“During acute withdrawal, neuroadaptations in the CeA, such as increased extracellular levels of the stress-related neuropeptide corticotrophin releasing factor (CRF), have been shown to mediate enhanced baseline anxiety and increased withdrawal-induced drug-seeking (34, 35).”
BackgroundPantazis, C. B., Gonzalez, L. A., Tunstall, B. J., Carmack, S. A., Koob, G. F., & Vendruscolo, L. F. (2021) · Science Advances · doi:10.1126/sciadv.abf0364 · Cited by 77
“L. Stinus, M. Cador, E. P. Zorrilla, G. F. Koob, Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats.”
BackgroundInfluentialSelf-citationBornebusch, A. B., Fink-Jensen, A., Wörtwein, G., Seeley, R. J., & Thomsen, M. (2019) · eneuro · doi:10.1523/eneuro.0443-18.2019 · Cited by 72
“…stimulants, nicotine, and opioids, and CRF antagonists can reduce effects of chronic opioid exposure including drug seeking and withdrawal symptoms, similar to effects observed with other drug classes (Shaham et al., 1998; Stinus et al., 2005; Park et al., 2015; for review, see Koob, 2008).”
BackgroundNegus, S. S., & Rice, K. C. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.127 · Cited by 70
“…opioid withdrawal, and it agrees with previous findings that CRF1 receptor antagonists attenuated both somatic withdrawal signs (Brugger et al, 1998; Iredale et al, 2000; Lu et al, 2000; Skelton et al, 2007) and withdrawal-induced place aversions (Heinrichs et al, 1995; Stinus et al, 2005) in rats.”
Jordan, C. J., Cao, J., Newman, A. H., & Xi, Z. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.04.015 · Cited by 79
“In morphine-dependent adults as well as rat pups, buprenorphine blocks withdrawal syndrome and withdrawal-induced conditioned place aversion (Stinus et al., 2005; Stoller and Smith, 2004).”
BackgroundErb, S. M. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.11.025 · Cited by 80
Disruption of the CRF/CRF1 Receptor Stress System Exacerbates the Somatic Signs of Opiate Withdrawal
Papaleo, F., Kitchener, P., & Contarino, A. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.022 · Cited by 71
Corticotropin-Releasing Factor (CRF) and Addictive Behaviors
Roberto, M., Spierling, S. R., Kirson, D., & Zorrilla, E. P. (2017) · International Review of Neurobiology · doi:10.1016/bs.irn.2017.06.004 · Cited by 56
Self-citationZaragoza, J. N., Núñez, C., Laorden, M. L., & Milanés, M. V. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.062463 · Cited by 63
“aversive effects of drug withdrawal (Stinus et al., 2005).”
Drug addiction: An affective-cognitive disorder in need of a cure
Fattore, L., & Diana, M. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.04.006 · Cited by 62
Phosphodiesterase 10A Regulates Alcohol and Saccharin Self-Administration in Rats
Logrip, M. L., Vendruscolo, L. F., Schlosburg, J. E., Koob, G. F., & Zorrilla, E. P. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.20 · Cited by 56
Self-citationNonmuscle myosin IIB as a therapeutic target for the prevention of relapse to methamphetamine use
Young, E. J., Blouin, A. M., Briggs, S. B., Daws, S. E., Lin, L., Cameron, M. D., Rumbaugh, G., & Miller, C. A. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.103 · Cited by 51
Kalange, A. S., Kokare, D. M., Singru, P. S., Upadhya, M. A., Chopde, C. T., & Subhedar, N. K. (2007) · Brain Research · doi:10.1016/j.brainres.2007.08.054 · Cited by 50
Glover, E. M., & Davis, M. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1112-0 · Cited by 51
“Interestingly, buprenorphine has been shown to block the acquisition of opioid-withdrawal-induced conditioned place aversion in rats (Stinus et al. 2005).”
BackgroundPhillips, T. J., Reed, C. L., & Pastor, R. (2015) · Genes Brain & Behavior · doi:10.1111/gbb.12189 · Cited by 51
“2002), and they may have little addiction liability (Broadbear et al. 2002; Sahuque et al. 2006; Stinus et al. 2005).”
Jaferi, A., & Pickel, V. M. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2008.12.061 · Cited by 45
“Increased activity in CRF systems within the brain is also thought to underlie the negative affective states and somatic/autonomic symptoms associated with morphine withdrawal (Lu et al, 2000; Iredale et al, 2000; Contarino & Papaleo, 2005; Stinus et al, 2005; Skelton et al, 2007).”
BackgroundDisruption of the CRF2 Receptor Pathway Decreases the Somatic Expression of Opiate Withdrawal
Papaleo, F., Ghozland, S. G., Ingallinesi, M., Roberts, A. J., Koob, G. F., & Contarino, A. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.8 · Cited by 48
Self-citationPotential Uses of Corticotropin‐Releasing Hormone Antagonists
Zoumakis, E., Rice, K. C., Gold, P. W., & Chrousos, G. P. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1367.021 · Cited by 43
Mitchell, J., Bergren, L. J., Chen, K. S., Rowbotham, M. C., & Fields, H. L. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.09.018 · Cited by 43
“As a number of systems, including dopamine and corticotropin releasing factor (CRF), have been shown to be involved in modulation of opioid agonist/antagonist induced dysphoria (Acquas et al., 1989; Stinus et al., 2005), any one of these may be contributing to the naltrexone aversion reported here.”
BackgroundOpioid withdrawal: role in addiction and neural mechanisms
Monroe, S. C., & Radke, A. K. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06370-2 · Cited by 53
Chapter, M. C., White, C. M., DeRidder, A. M., Chadwick, W., Martin, B., & Maudsley, S. R. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.07.006 · Cited by 45
Cocaine, Hormones, and Behavior: Clinical and Preclinical Studies
Mello, N. K., & Mendelson, J. H. (2009) · Elsevier eBooks · doi:10.1016/b978-008088783-8.00098-x · Cited by 39
Development of medications for alcohol use disorders: recent advances and ongoing challenges
Litten, R. Z., Fertig, J. B., Mattson, M. E., & Egli, M. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.2.323 · Cited by 40
“CRF1 antagonists may also be beneficial in treating other disorders, including anxiety, depression and opioid withdrawal [147-149].”
BackgroundWang, L., Shen, M., Jiang, C., Ma, L., & Wang, F. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw060 · Cited by 29
Zaragoza, J. N., Núñez, C., Ruiz‐Medina, J., Laorden, M. L., Valverde, O., & Milanés, M. V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01090.x · Cited by 35
“…central amygdala, the bed nucleus of the stria terminalis (important components of the extended amygdala) and the PVN. CRF British Journal of Pharmacology (2011) 162 851–862 859 from these nuclei would induce the release of NA by the brain stem noradrenergic areas (Koob, 1999; Stinus et al., 2005).”
BackgroundConverging vulnerability factors for compulsive food and drug use
Serafine, K. M., O’Dell, L. E., & Zorrilla, E. P. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108556 · Cited by 30
“…Bruijnzeel et al. (2009); Bruijnzeel et al. (2010); Knapp et al. (2004); Overstreet et al. (2004); Sommer et al. (2008); Skelton et al. (2007); Stinus et al. (2005); Basso et al. (1999); Sarnyai et al. (1995); George et al. (2007); Chu et al. (2007); Funk et al. (2007); Gehlert et al.…”
BackgroundSelf-citationReinforcement principles for addiction medicine; from recreational drug use to psychiatric disorder
Edwards, S. (2015) · Progress in brain research · doi:10.1016/bs.pbr.2015.07.005 · Cited by 36
The effects of buprenorphine on fentanyl withdrawal in rats
Bruijnzeel, A. W., Marcinkiewcz, C. A., Isaac, S. K., Booth, M. M., Dennis, D. M., & Gold, M. S. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0670-2 · Cited by 33
“Koob and colleagues investigated the effects of buprenorphine on the aversive effects of naloxone-precipitated morphine withdrawal (Stinus et al. 2005).”
Backgroundde la Tremblaye, P. B., & Plamondon, H. (2016) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2016.07.001 · Cited by 28
“…aversion and the negative affective state produced by precipitated opiate withdrawal (Contarino and Papaleo, 2005; Navarro-Zaragoza et al., 2010; Stinus et al., 2005), and reduces ACTH hypersecretion, dopamine turnover and TH phosphorylation in the NAc of morphine withdrawn rats (Almela et al.,…”
BackgroundToward a systems-oriented approach to the role of the extended amygdala in adaptive responding
Waraczynski, M. A. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.05.015 · Cited by 31
Wills, K. L., & Parker, L. A. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00187 · Cited by 33
“In evaluating the role of the endocannabinoid system in affective opioid withdrawal, the CPA paradigm has been most commonly Frontiers in Pharmacology | www.frontiersin.org 2 June 2016 | Volume 7 | Article 187”
BackgroundMethodAllostasis theory in opioid tolerance
Ballantyne, J. C., & Koob, G. F. (2021) · Pain · doi:10.1097/j.pain.0000000000002280 · Cited by 28
Self-citationAlmela, P., Zaragoza, J. N., García-Carmona, J. A., Mora, L., Hidalgo, J. M., Milanés, M. V., & Laorden, M. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047089 · Cited by 33
“Accordingly, antagonism of CRF neurotransmission attenuated the anxiety-like and aversive effects of drug withdrawal [14].”
BackgroundCorticotropin-Releasing Hormone Receptor Antagonists: An Update
Zoumakis, E., & Chrousos, G. P. (2009) · Endocrine development · doi:10.1159/000262526 · Cited by 23
Glass, M. J. (2010) · Vitamins and hormones · doi:10.1016/s0083-6729(10)82008-4 · Cited by 24
“This result is similar to other findings in the literature showing that blockade of CeA CRF receptors also inhibits physical symptoms of withdrawal from opioids (McNally and Akil, 2002).”
Corley, C. L., Craig, A. J., Sadek, S. M., Marusich, J. A., Chehimi, S. N., White, A. M., Holdiness, L. J., Reiner, B. C., & Gipson, C. D. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173836 · Cited by 27
“…buprenorphine increases elasticity of fentanyl demand using an operant SA economic demand task (Hammerslag et al., 2020); although somatic signs of withdrawal were not evaluated in that study) and also blocks opioid withdrawal-induced conditioned place aversion in rats (Stinus et al., 2005).”
BackgroundGarcía-Carmona, J. A., Almela, P., Baroja‐Mazo, A., Milanés, M. V., & Laorden, M. L. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2478-y · Cited by 25
“The existence of a NA-CRF loop has been proposed in which NA would modulate the release of CRF in the brain stress system, including the central amygdala, the bed nucleus of stria terminalis and the paraventricular nucleus of hypothalamus (PVN).”
BackgroundInfluentialValero, E., Gómez-Milanés, I., Almela, P., Couto, B. R. D., Laorden, M. L., Milanés, M. V., & Núñez, C. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.01.018 · Cited by 22
“Moreover, our results support the idea that targeting CRF1R may provide important insights into the role of these signaling cascades in withdrawal-context memory retrieval, as has been previously proposed (Stinus et al., 2005).”
Mattioli, L., & Perfumi, M. C. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109359096 · Cited by 20
“Moreover, it has been reported that pretreatment with CRF antagonists can reduce several signs of opiate withdrawal (e.g. jumping, teeth chattering, writhing) (Heinrichs et al., 1995; Papaleo et al., 2007, 2008; Stinus et al., 2005).”
BackgroundMantsch, J. R. (2022) · Addiction Neuroscience · doi:10.1016/j.addicn.2022.100038 · Cited by 25
Ferracane, M. J., Brice‐Tutt, A. C., Coleman, J. S., Simpson, G. G., Wilson, L., Eans, S. O., Stacy, H. M., Murray, T. F., McLaughlin, J. P., & Aldrich, J. V. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00086 · Cited by 21
Mello, N. K., Negus, S. S., Rice, K. C., & Mendelson, J. H. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.11.008 · Cited by 21
McFalls, A. J., Imperio, C. G., Bixler, G. V., Freeman, W. M., Grigson, P. S., & Vrana, K. E. (2015) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2015.11.009 · Cited by 17
Umathe, S. N., Mundhada, Y. R., & Bhutada, P. (2012) · Neuropeptides · doi:10.1016/j.npep.2012.06.002 · Cited by 17
“and also the involvement of corticotrophin-releasing factor (CRF) type-1 and type-2 receptor in the modulation of multiple behavioral and neurobiological processes of morphine withdrawal (Hamlin et al., 2004; Lu et al., 2005; Stinus et al., 2005; Skelton et al., 2007; Lee et al., 2011; Navarro-Zaragoza et al., 2011; G…”
BackgroundResultMorisot, N., & Contarino, A. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.02.021 · Cited by 16
“Initial studies using pharmacological agents show that CRF receptor antagonism attenuates either the somatic signs or the negative affective-like states of naloxone-precipitated opiate withdrawal (Heinrichs et al., 1995; Iredale et al., 2000; Lu et al., 2000; Stinus et al., 2005).”
BackgroundBaidoo, N., Wolter, M., Holahan, M. R., Epp, T., Winters, B. D., & Leri, F. (2020) · Addiction Biology · doi:10.1111/adb.12909 · Cited by 19
Opioids and addiction: Emerging pharmaceutical strategies for reducing reward and opponent processes
Bryant, C. D., Zaki, P. A., Carroll, F. I., & Evans, C. J. (2005) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2005.08.006 · Cited by 17
“[114] Stinus L, Cador M, Zorrilla EP, Koob GF.”
InfluentialSolecki, W., Kuś, N., Gralec, K., Klasa, A., Pradel, K., & Przewłocki, R. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.11.041 · Cited by 16
“Importantly, morphine withdrawal-related changes in the affective/motivational state could be readily measured in the CPA paradigm [59,60].”
Li, Y., Liu, X., Chen, H., Deng, H., Xiang, X., Chen, H., & Hao, W. (2007) · Addiction Biology · doi:10.1111/j.1369-1600.2007.00059.x · Cited by 15
Tzschentke, T., Magalas, Z., & Vry, J. D. (2006) · Addiction Biology · doi:10.1111/j.1369-1600.2006.00009.x · Cited by 17
Overview of Nicotine Withdrawal and Negative Reinforcement (Preclinical)
George, O., & Koob, G. F. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802574-1.00001-6 · Cited by 20
Self-citationCorticotropin-releasing hormone receptor antagonists
Zoumakis, E., Grammatopoulos, D. K., & Chrousos, G. P. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02259 · Cited by 14
The dark side of compulsive eating and food addiction
Zorrilla, E. P., & Koob, G. F. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816207-1.00006-8 · Cited by 23
Self-citationBrain stress system response after morphine-conditioned place preference
García-Carmona, J. A., Milanés, M. V., & Laorden, M. L. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000588 · Cited by 14
“Conversely, CRF from these nuclei induces the release of noradrenaline (NA) by the brainstem noradrenergic areas (Koob, 1999; Stinus et al., 2005).”
BackgroundLearning and Memory in Addiction
Carmack, S. A., Koob, G. F., & Anagnostaras, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.21101-2 · Cited by 17
Self-citationCardiac Protective Role of Heat Shock Protein 27 in the Stress Induced by Drugs of Abuse
Laorden, E. M., Zaragoza, J. N., Milanés, M. V., Laorden, M. L., & Almela, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103623 · Cited by 13
“This axis activates noradrenergic neurons in the nucleus of the tractus solitarius and the ventrolateral medulla, which are implicated in cardiac function [38,39].”
BackgroundNeurobiological Theories of Addiction
Koob, G. F., & Moal, M. L. (2006) · Elsevier eBooks · doi:10.1016/b978-012419239-3/50046-1 · Cited by 11
Self-citationAnimal Models of Drug Dependence: Motivational Perspective
Koob, G. F. (2010) · Springer eBooks · doi:10.1007/978-1-4419-0338-9_15 · Cited by 10
Self-citationJaferi, A., Zhou, P., & Pickel, V. M. (2010) · Synapse · doi:10.1002/syn.20810 · Cited by 10
“…pharmacological blockade of the CRF-1 receptor attenuates stress-induced relapse to opiate seeking (Shaham et al., 1998; Wang et al., 2006) as well as the somatic and affective symptoms of opiate withdrawal (Contarino and Papaleo, 2005; Iredale et al., 2000; Lu et al., 2000; Stinus et al., 2005).”
BackgroundDrug addiction co-morbidity with alcohol: Neurobiological insights
McGinn, M. A., Pantazis, C. B., Tunstall, B. J., Marchette, R. C. N., Carlson, E. R., Said, N., Koob, G. F., & Vendruscolo, L. F. (2021) · International review of neurobiology · doi:10.1016/bs.irn.2020.11.002 · Cited by 12
Self-citationDiscriminative Stimulus Properties of Opioid Ligands: Progress and Future Directions
Butelman, E. R., & Kreek, M. J. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_9 · Cited by 8
Zaragoza, J. N., Laorden, E. M., Mora, L., Hidalgo, J. M., Milanés, M. V., & Laorden, M. L. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.12.021 · Cited by 9
Li, J., Shao, D., Jiang, D., Huang, Q., Guan, Y., Lai, B., Zhao, J., Hua, F., & Xie, F. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00849-9 · Cited by 7
Metadata
- Authors
- Stinus, L., Cador, M., Zorrilla, E. P., & Koob, G. F.
- Affiliations
- Université de Bordeaux (FR)
- Scripps Research Institute (US)
- Corresponding author
- Stinus, Luis
- Venue
- Neuropsychopharmacology
- Published
- 2004-05-12
- Volume
- 30
- Issue
- 1
- Pages
- 90-98
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1980693070
- Cited by
- 139
- References
- 73
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 6 · 2020: 7 · 2019: 6 · 2018: 4 · 2017: 3 · 2016: 10 · 2015: 6 · 2014: 8 · 2013: 6 · 2012: 6
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Université de Bordeaux
- National Institutes of Health
- National Institute on Drug Abuse (DA04043, R01DA004043)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- buprenorphine, corticotropin-releasing factor 1 receptor, antalarmin, opioid withdrawal, conditioned place aversion, morphine dependence, naloxone, place conditioning, acamprosate, terguride, fluoxetine, glutamate receptor modulation
- MeSH terms
- Acamprosate, CRF Receptor, Type 1, Analgesics, Opioid, Animals, Avoidance Learning, Buprenorphine, Conditioning, Operant, Dose-Response Relationship, Drug, Drug Implants, Fluoxetine, Lisuride, Male, Morphine, Naloxone, Narcotic Antagonists, Opioid-Related Disorders, Narcotics, Pyrimidines, Pyrroles, Substance Withdrawal Syndrome, Taurine, Rats, Sprague-Dawley, Receptors, Corticotropin-Releasing Hormone, Antidepressive Agents, Second-Generation, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.